Treatment method	Stratification*	Grade I recommendations	Grade II recommendations	Grade III recommendations
Postoperative adjuvant treatment	pT3–4NanyM0 pTanyN + M0 R0 D2 resection	Postoperative adjuvant chemotherapy: XELOX (Evidence 1A) S-1 alone (Evidence 1A)	Postoperative adjuvant chemotherapy: FOLFOX (Evidence 2A) SOX (Evidence 2A)	Postoperative adjuvant chemotherapy: XP (Evidence 2B) Postoperative adjuvant chemoradiotherapy: DT 45–50.4 Gy (concurrent fluoropyrimidine) (Evidence 3)
	pT2-4NanyM0, R0 resection; Failing to meet criteria for D2	Postoperative chemoradiotherapy: DT 45–50.4 Gy (concurrent fluoropyrimidine) (Evidence 1A)	MDT discussion for optimal treatment regimen
	pT2-4NanyM0 R1/R2 resection	Postoperative chemoradiotherapy: DT 45 to 50.4 Gy (concurrent fluoropyrimidine)	MDT discussion for optimal treatment regimen

XELOX oxaliplatin (xeloda) + capecitabine, FOLFOX leucovorin calcium (folinic acid) + fluorouracil + oxaliplatin, SOX S-1 + oxaliplatin, XP capecitabine + cisplatin

* According to the 8th AJCC/UICC pathological staging system (pTNM) for gastric cancer